Blueprint Medicines Signs an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize BLU-945 and BLU-701 in Greater China
Shots:
- Blueprint will receive $25M up front, ~$590M in milestones along with royalties on net sales of BLU-945 & BLU-701 in Greater China & will retain all rights to BLU-945 & BLU-701 globally
- Zai Lab will get the rights to develop & exclusively commercialize BLU-945 & BLU-701 in Greater China & will lead the development costs for both products
- The collaboration combines Blueprint's precision therapy expertise with Zai Lab's development capabilities to accelerate the global development of BLU-945 & BLU-701 for NSCLC. Additionally, BLU-945 is currently being evaluated in the P-I/II SYMPHONY trial for EGFR-driven NSCLC & P-I/II trial of BLU-701 is expected to initiate in Q4'21
Ref: PR Newswire | Image: Blueprint
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com